Navigation Links
Abbott's Humira(r) (Adalimumab) Gets Approval by EU for Crohn's Disease Treatment

ABBOTT PARK, Ill., Abbott announced today that it has received marketing authorization from the European Commission for the use of HUMIRA(R) (adalimumab) as a treatment for severe Crohn's disease. HUMIRA is the first self-administered biologic for the treatment of Crohn's disease and offers an effective and convenient treatment option that can help enable patients to maintain control of their disease. This announcement follows FDA approval for the Crohn's disease indication, which Abbott received in February, and is the fourth approved indication for HUMIRA in the United States and the European Union.

Crohn's disease is a serious, chronic, inflammatory disease of the gastrointestinal (GI) tract that affects more than 1 million people in North America and Europe. It affects people of all ages, but it is primarily a disease of young adults, with onset typically before age 40. There is no medical or surgical cure for Crohn's disease and few treatment options exist for patients suffering with this chronic condition.

"Crohn's can have a devastating impact on patients, many of whom are young and active, making it difficult to carry out normal day-to-day activities," said Rod Mitchell, chairman, European Federation of Crohn's & Ulcerative Colitis Associations. "The unpredictable nature of the disease can seriously impact their quality of life and self-esteem. For the half million people across Europe suffering from Crohn's, this approval offers hope to help them regain control of their disease."

Common symptoms of Crohn's disease include diarrhea, cramping, abdominal pain, weight loss, fever, and in some cases, rectal bleeding. Complications include intestinal obstruction, fistulas (ulcers that form tunnels to surrounding tissues), and malnutrition. Over the course of their disease, as many as 75 percent of patients with Crohn's disease will undergo surgery at least once for complications or disease resistant to treatment. Of thos
'"/>




Page: 1 2

Related medicine news :

1. Approval for DNA test to detect cystic fibrosis
2. Vaccine For Cervical Cancer Awaits Approval
3. WHO Gives Its Approval For Bird Flu Test Kit
4. FDA Gives Its Approval For Inhaler
5. RotaTeq Gets US Approval
6. Better Communication With FDA Could Speed Up Approval Of New Drugs
7. Nerve Stimulator for Depression Though Not Effective Was Given Approval
8. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
9. Global Education Net Pvt Medical College Gets MCI Approval
10. Approval of Drugs for the Treatment of Late-Stage Cancer
11. Lupin Gets USFDA Approval For Quinapril Tablets
Post Your Comments:
(Date:8/28/2015)... ... August 28, 2015 , ... ... high grade protein with zero fat, carbs, sugar, gluten, lactose or caffeine in ... finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged ...
(Date:8/28/2015)... Neb. (PRWEB) , ... August 28, 2015 , ... Medical ... the 2015 Best Places to Work in Healthcare by Modern Healthcare and ... , Now in its eighth year, the Best Places to Work in ...
(Date:8/28/2015)... ... August 28, 2015 , ... SmartPractice Calendars ... Personalized with practice contact information and logos, Calendars stand alone as functional brand-building ... Calendars into seasonal mailings, thank you and welcome communications, and to complement statements ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... to announce its collaboration with coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and ... It features revolutionary Thermal Flavor Extraction™ technology, which delivers a variety of sizes ...
(Date:8/28/2015)... (PRWEB) , ... August 28, ... ... Services, Inc.’s (AIS) Medicare-Medicaid Dual Eligibles Database have added comprehensive information on ... alignment demonstration approved for a December 2015 launch; and Idaho’s partnership to ...
Breaking Medicine News(10 mins):Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2
... The Centers for Disease Control and Prevention ( ... leading cause of death. In 2009, an estimated ... attack, and about 470,000 will have a recurrent ... of people nationwide focus on education and provide ...
... brings extensive experience in neuroscience and oncology to ... therapeutic categories , , ROCKVILLE, Md. ... Pharmaceutical, Inc. (OAPI), a fast-growing health care company ... North America, has announced the appointment of Mark ...
... Pharmaceutical Services, Inc. (NYSE: WST ) announced ... results before the market opens on Thursday, February 19, ... discuss the results and business expectations at 9:00 a.m. ... (888)790-3758 or (210)839-8398. The passcode is WST.A live broadcast ...
... Additional $2.5 MillionCRANBURY, N.J., Feb. 12 Palatin ... it has received $4.1 million from AstraZeneca relating ... and license agreement to discover, develop and commercialize ... trial sponsored research agreement. Palatin also announced that ...
... discuss fourth quarter financial results -LAVAL, QC, Feb. 12 ... DDSS ) today announced that it will host a ... (ET) to discuss its fourth quarter 2008 financial results. ... via news release at approximately 7:00 a.m. the same ...
... Inc. (OTC Bulletin Board: DORB) (DOR or the Company) ... million partnering agreement with Sigma - Tau Pharmaceuticals, Inc. ... North America of orBec(R) (oral beclomethasone dipropionate or Oral ... make a $6 million upfront investment in DOR, inclusive ...
Cached Medicine News:Health News:The ISSA Offers 8 Tips for American Heart Month 2Health News:Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer 2Health News:Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer 3Health News:Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer 4Health News:Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer 5Health News:Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer 6Health News:West to Host 2008 Fourth Quarter Conference Call 2Health News:Palatin Technologies Announces Receipt of $4.1 Million from AstraZeneca 2Health News:Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET) 2Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 2Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 3Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 4Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 5Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 6Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 7
(Date:8/28/2015)... and PITTSBURGH , Aug. 28, ... today announced that its shareholders have approved Mylan,s ... PRGO ; TASE) and the related issuance of ... extraordinary general meeting of shareholders held today. The ... at the extraordinary general meeting. In addition, the ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de 2015 /PRNewswire/ ... hoy su participación en el  Congreso de la ... cardiológicas más recientes y novedosas, entre ellas HeartModel ... a las personas y la tecnología con los ... diagnosticar, guiar los tratamientos y permitir atención en ...
(Date:8/27/2015)... , Aug. 27, 2015  The Academy of ... and Drug Administration,s (FDA,s) draft guidance and proposed ... and biosimilars, to bear a nonproprietary name with ... been seeking a decision from the FDA on ... health care stakeholders urging the agency to use ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
... Cornerstone Therapeutics Inc. (Nasdaq: CRTX ), a specialty ... primarily for the respiratory and related markets, today announced that ... ET on Tuesday, May 4, 2010 , to ... 31, 2010 .  Management will also provide an update on ...
... International Merchant Advisors, Inc. (Pink Sheets: IMAI) www.imaiinc.com ... Science, Inc., intends to launch a national line of medical marijuana ... in the new CNBC article "Marijuana and Money" www.cnbc.com , ... $109 billion per year. , ...
Cached Medicine Technology:Cornerstone Therapeutics to Host First Quarter 2010 Conference Call 2Cornerstone Therapeutics to Host First Quarter 2010 Conference Call 3International Merchant Advisors to Develop Organic Science Branded Medical Marijuana Product Line 2International Merchant Advisors to Develop Organic Science Branded Medical Marijuana Product Line 3
Soft PVC. Available in sizes 12-36F, Interior striations for smooth suction catheter insertion. Bevel tip. Single use. Sterile....
Soft Guedel Oral Airways...
... airways., ,When a difficult airway must ... Now you can be assured of rapid ... Esophageal/Tracheal double-Lumen Airway from Nellcor. Unlike traditional ... to establish a nonsurgical patient airway when ...
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
Medicine Products: